JP2021502984A5 - - Google Patents

Download PDF

Info

Publication number
JP2021502984A5
JP2021502984A5 JP2020526504A JP2020526504A JP2021502984A5 JP 2021502984 A5 JP2021502984 A5 JP 2021502984A5 JP 2020526504 A JP2020526504 A JP 2020526504A JP 2020526504 A JP2020526504 A JP 2020526504A JP 2021502984 A5 JP2021502984 A5 JP 2021502984A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
seq
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020526504A
Other languages
English (en)
Japanese (ja)
Other versions
JP7841846B2 (ja
JP2021502984A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/081296 external-priority patent/WO2019096874A1/en
Publication of JP2021502984A publication Critical patent/JP2021502984A/ja
Publication of JP2021502984A5 publication Critical patent/JP2021502984A5/ja
Priority to JP2025269754A priority Critical patent/JP2026040534A/ja
Application granted granted Critical
Publication of JP7841846B2 publication Critical patent/JP7841846B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020526504A 2017-11-15 2018-11-15 Fx活性化を促進する第x因子結合剤 Active JP7841846B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025269754A JP2026040534A (ja) 2017-11-15 2025-12-19 Fx活性化を促進する第x因子結合剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17201762.6 2017-11-15
EP17201762 2017-11-15
EP18174634 2018-05-28
EP18174634.8 2018-05-28
PCT/EP2018/081296 WO2019096874A1 (en) 2017-11-15 2018-11-15 Factor x binders enhancing fx activation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025269754A Division JP2026040534A (ja) 2017-11-15 2025-12-19 Fx活性化を促進する第x因子結合剤

Publications (3)

Publication Number Publication Date
JP2021502984A JP2021502984A (ja) 2021-02-04
JP2021502984A5 true JP2021502984A5 (https=) 2021-12-02
JP7841846B2 JP7841846B2 (ja) 2026-04-07

Family

ID=64426877

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020526504A Active JP7841846B2 (ja) 2017-11-15 2018-11-15 Fx活性化を促進する第x因子結合剤
JP2025269754A Pending JP2026040534A (ja) 2017-11-15 2025-12-19 Fx活性化を促進する第x因子結合剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025269754A Pending JP2026040534A (ja) 2017-11-15 2025-12-19 Fx活性化を促進する第x因子結合剤

Country Status (7)

Country Link
US (2) US11787874B2 (https=)
EP (2) EP4667496A2 (https=)
JP (2) JP7841846B2 (https=)
CN (2) CN111386285B (https=)
ES (1) ES3050257T3 (https=)
MA (1) MA50893A (https=)
WO (1) WO2019096874A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
JP7841846B2 (ja) * 2017-11-15 2026-04-07 ノヴォ ノルディスク アー/エス Fx活性化を促進する第x因子結合剤
US10815308B2 (en) 2018-12-21 2020-10-27 Kymab Limited FIXaxFX bispecific antibody with common light chain
JP2022548783A (ja) 2019-09-23 2022-11-21 ツイスト バイオサイエンス コーポレーション 単一ドメイン抗体のバリアント核酸ライブラリー
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
EP4314075A4 (en) * 2021-03-24 2025-04-09 Twist Bioscience Corporation VARIANT NUCLEIC ACID BANKS FOR CD3
WO2023111018A1 (en) * 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Antibodies against coagulation factor x and uses thereof
WO2023225035A2 (en) * 2022-05-16 2023-11-23 Artisan Development Labs, Inc. Compositions and methods for engineering cells
US12098400B2 (en) * 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
IL317317A (en) * 2022-07-08 2025-01-01 Novo Nordisk As Highly potent ISVD compounds capable of replacing FVIII(A)
CN115960227A (zh) * 2022-11-08 2023-04-14 河南赛诺特生物技术有限公司 一种抗人msh2的单克隆抗体及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
CA2143126A1 (en) 1993-07-01 1995-01-12 Shamay Tang Process for the preparation of factor x depleted plasma
WO2000007626A1 (en) 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2004041863A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
PT1876236E (pt) 2005-04-08 2014-10-22 Chugai Pharmaceutical Co Ltd Anticorpos para substituição da função do factor de coagulação sanguínea viii
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
EP2915564B1 (en) 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
TWI831106B (zh) 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
JP6698102B2 (ja) 2015-04-17 2020-05-27 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 凝固因子と多重特異的抗体を用いた併用療法
US20190185578A1 (en) 2016-07-29 2019-06-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
PL3509637T3 (pl) 2016-09-06 2025-03-10 Chugai Seiyaku Kabushiki Kaisha Sposoby zastosowania dwuswoistego przeciwciała, które rozpoznaje czynnik krzepnięcia IX i/lub aktywowany czynnik krzepnięcia IX oraz czynnik krzepnięcia X i/lub aktywowany czynnik krzepnięcia X
TN2019000164A1 (en) 2016-11-23 2020-10-05 Bioverativ Therapeutics Inc Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
JP7841846B2 (ja) * 2017-11-15 2026-04-07 ノヴォ ノルディスク アー/エス Fx活性化を促進する第x因子結合剤

Similar Documents

Publication Publication Date Title
JP2021502984A5 (https=)
JP2020536504A5 (https=)
JP2021191763A5 (https=)
JP2015163068A5 (https=)
JP2018121657A5 (https=)
JP2019054802A5 (https=)
JP2020525032A5 (https=)
JP2021530251A5 (https=)
JP2018521638A5 (https=)
JP2015504421A5 (https=)
JP2017504578A5 (https=)
RU2016100892A (ru) Антитела против tweakr и их применение
WO2016207304A8 (en) Monoclonal anti-il-1racp antibodies
JP2017533694A5 (https=)
RU2014122990A (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas
JP2019504032A5 (https=)
JP2018517431A5 (https=)
JP2019506412A5 (https=)
JP2018527919A5 (https=)
JP2020524510A5 (https=)
JP2017505125A5 (https=)
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
JP2018522888A5 (https=)
JP2022533538A5 (https=)